Advertisement
INGN vs VCYT
Which Stock Would AI Choose? Inogen (INGN) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- Scale and market positioning diverge sharply: VCYT commands a market capitalization of approximately $4.4 billion, while INGN sits near $171 million, reflecting fundamentally different stages of business maturity.
- Profitability trajectories contrast: VCYT delivered GAAP (Generally Accepted Accounting Principles) net income of $66.4 million in fiscal 2025 alongside a 27.6% adjusted EBITDA margin (Earnings Before Interest, Taxes, Depreciation, and Amortization). INGN, though improving, reported a GAAP net loss of $22.7 million for the same year.
- Revenue growth favors VCYT: VCYT grew full-year 2025 revenue by 16% to $517 million, powered by double-digit genomic testing volume expansion. INGN achieved 4% revenue growth to $348.7 million, constrained by declining direct-to-consumer sales.
- Risk profiles differ materially: INGN is executing a turnaround strategy with a debt-free balance sheet and $120.9 million in cash, while VCYT carries a premium valuation at over 50 times trailing earnings, exposing it to multiple-compression risk.
- Both operate in healthcare but address distinct end markets: INGN serves the chronic respiratory care segment, whereas VCYT competes in the high-growth oncology diagnostics industry.
Introduction
Investors evaluating healthcare equities often encounter companies at vastly different stages of their corporate lifecycle. That dynamic is on full display when comparing Inogen, Inc. (INGN) and Veracyte, Inc. (VCYT) — two Nasdaq-listed medical technology firms that share a sector but little else in terms of scale, profitability, and market momentum. INGN is a legacy player in portable respiratory devices navigating a multi-year turnaround, while VCYT has emerged as a fast-growing force in genomic cancer diagnostics. This comparison is particularly relevant for traders and investors seeking to understand how growth-stage profitability, turnaround dynamics, and valuation premiums influence relative stock performance in the current market environment.
INGN Overview and Recent Performance
Inogen (INGN) develops, manufactures, and markets portable oxygen concentrators (POCs) and related respiratory therapy products for the homecare setting. The company has been transitioning from a single-product POC manufacturer into a diversified respiratory care platform, recently expanding into stationary oxygen concentrators, CPAP (Continuous Positive Airway Pressure) masks for sleep apnea, and airway clearance devices.
In recent months, INGN has shown measured operational progress. Full-year 2025 revenue reached $348.7 million, representing approximately 4% year-over-year growth. International sales were a standout, growing roughly 18.4%, while U.S. direct-to-consumer sales continued to contract. In a notable milestone, INGN achieved positive adjusted EBITDA of $2.7 million for 2025 — its first annual profitability on this metric since 2021. The company closed 2025 with $120.9 million in cash and equivalents and no outstanding debt, providing financial runway for its turnaround.
The stock has traded within a 52-week range of approximately $5.34 to $9.13, with a current market capitalization near $171 million. Sentiment has been tempered by persistent GAAP losses and declining rental revenue, though the company's $30 million share repurchase authorization and 2026 revenue guidance of $366 million to $373 million have provided some support for the equity narrative.
VCYT Overview and Recent Performance
Veracyte (VCYT) is a leading cancer diagnostics company that provides genomic testing products — primarily the Decipher Prostate genomic classifier and the Afirma thyroid cancer test — to guide treatment decisions across prostate, thyroid, breast, and bladder cancers. Its testing platform combines RNA sequencing, machine-learning algorithms, and clinical evidence to generate high-value diagnostic insights.
VCYT's recent performance has been defined by sustained double-digit revenue growth and rapidly expanding profitability. Full-year 2025 revenue climbed 16% to $517.1 million, with testing revenue alone growing roughly 17-18% to approximately $492 million. Decipher prostate test volume rose approximately 27% year-over-year, marking multiple consecutive quarters of 25%-plus volume growth. Afirma thyroid testing posted 11% volume growth. Adjusted EBITDA margin reached 27.6% for the full year, surpassing management's stated target.
The company reported GAAP net income of $66.4 million for 2025 — a dramatic shift from prior-year losses — and ended the year with approximately $412.9 million in cash. VCYT shares have rallied substantially over the trailing twelve months, with the 52-week range spanning roughly $22.92 to $60.91 and the market capitalization now exceeding $4.4 billion. Upcoming catalysts include the 2026 launches of the TrueMRD (Minimal Residual Disease) platform for bladder cancer monitoring and the Prosigna breast cancer test as an LDT (Laboratory Developed Test) in the U.S. market.
Trending AI Robots
For traders who prefer a data-driven approach to navigating markets like the one shaping the trajectories of INGN and VCYT, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only the top performers most suited to current market conditions earn a place in this section. These bots span a wide range of trading styles — from short-term swing trading to trend-following strategies — and vary in timeframes, risk parameters, and historical performance statistics. Some bots specialize in specific sectors, while others scan the entire market for opportunity. Each bot's track record, win rate, and trade frequency are transparently displayed, allowing users to find a strategy aligned with their own risk tolerance and objectives. Exploring the Trending AI Robots can help investors identify algorithmic strategies currently generating signals in names like INGN, VCYT, and beyond.
Head-to-Head Comparison
The most immediate distinction between INGN and VCYT is scale: VCYT's market capitalization is roughly 26 times larger than INGN's. But the divergence runs deeper than size. VCYT operates a high-margin, recurring-revenue diagnostic testing model with gross margins near 73% (non-GAAP) and rapidly improving operating leverage. INGN, by contrast, is a hardware-focused medical device company with gross margins in the 43-45% range and a cost structure still burdened by the turnaround of its legacy direct-to-consumer sales channel.
On the growth front, VCYT's 16% revenue expansion in 2025 — driven by volume gains in Decipher and Afirma — meaningfully outpaced INGN's 4% growth. VCYT is also entering new addressable markets through its MRD and Prosigna LDT initiatives, whereas INGN's growth catalysts — the Voxi 5 stationary concentrator, Aurora CPAP masks, and the Simeox airway clearance device — remain earlier in their commercial ramp.
Valuation tells its own story. VCYT trades at a trailing P/E (Price-to-Earnings) ratio above 50 and a forward P/E above 31, reflecting market confidence in sustained double-digit growth. INGN has no meaningful P/E ratio due to negative GAAP earnings but trades at roughly 0.5 times trailing revenue and approximately 0.93 times book value, pricing in substantial uncertainty about the turnaround's timeline.
Risk factors also differ. VCYT's premium valuation creates vulnerability to any slowdown in Decipher volume growth or delays in new product launches. INGN's risk lies in execution — whether the company can convert its improving adjusted EBITDA trajectory into sustained GAAP profitability before cash reserves become a concern.
Tickeron AI Verdict
Based on observable trends in momentum, profitability, and growth consistency, Tickeron's AI-driven analytical framework would likely favor VCYT in the current market environment. The stock's combination of sustained double-digit revenue growth, GAAP profitability, expanding margins, and multiple upcoming product catalysts presents a more consistent trend profile than INGN's ongoing turnaround story. VCYT's stronger technical score and higher relative strength over recent quarters reinforce this probabilistic assessment. That said, INGN's debt-free balance sheet, improving adjusted EBITDA trajectory, and deep-value trading multiples could appeal to an AI strategy oriented toward mean reversion or contrarian positioning. The outcome is strategy-dependent: trend-following algorithms would more likely favor VCYT, while deep-value or turnaround-oriented models might find INGN's risk-reward profile increasingly compelling as operational improvements accumulate.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INGN is a Hold and VCYT is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INGN’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).
- INGN’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INGN’s TA Score shows that 3 TA indicator(s) are bullish while VCYT’s TA Score has 5 bullish TA indicator(s).
- INGN’s TA Score: 3 bullish, 6 bearish.
- VCYT’s TA Score: 5 bullish, 4 bearish.
Price Growth
INGN (@Medical/Nursing Services) experienced а +4.88% price change this week, while VCYT (@Medical Specialties) price change was -18.18% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
Reported Earning Dates
INGN is expected to report earnings on Aug 06, 2026.
VCYT is expected to report earnings on Nov 10, 2026.
Industries' Descriptions
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| INGN | VCYT | INGN / VCYT | |
| Capitalization | 175M | 3.7B | 5% |
| EBITDA | -11.51M | 137M | -8% |
| Gain YTD | -4.018 | 10.024 | -40% |
| P/E Ratio | N/A | 33.09 | - |
| Revenue | 351M | 562M | 62% |
| Total Cash | 110M | 485M | 23% |
| Total Debt | 16.9M | 40.1M | 42% |
INGN | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 60 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 87 | |
SMR RATING 1..100 | 96 | 76 | |
PRICE GROWTH RATING 1..100 | 57 | 41 | |
P/E GROWTH RATING 1..100 | 58 | 91 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VCYT's Valuation (60) in the Biotechnology industry is in the same range as INGN (85) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to INGN’s over the last 12 months.
VCYT's Profit vs Risk Rating (87) in the Biotechnology industry is in the same range as INGN (100) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to INGN’s over the last 12 months.
VCYT's SMR Rating (76) in the Biotechnology industry is in the same range as INGN (96) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to INGN’s over the last 12 months.
VCYT's Price Growth Rating (41) in the Biotechnology industry is in the same range as INGN (57) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to INGN’s over the last 12 months.
INGN's P/E Growth Rating (58) in the Medical Specialties industry is somewhat better than the same rating for VCYT (91) in the Biotechnology industry. This means that INGN’s stock grew somewhat faster than VCYT’s over the last 12 months.
| INGN | VCYT | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 79% | 4 days ago 79% |
| Momentum ODDS (%) | 4 days ago 77% | 4 days ago 81% |
| MACD ODDS (%) | 4 days ago 90% | 4 days ago 80% |
| TrendWeek ODDS (%) | 4 days ago 73% | 4 days ago 80% |
| TrendMonth ODDS (%) | 4 days ago 72% | 4 days ago 85% |
| Advances ODDS (%) | 6 days ago 69% | 5 days ago 73% |
| Declines ODDS (%) | 11 days ago 83% | 8 days ago 79% |
| BollingerBands ODDS (%) | 4 days ago 73% | 4 days ago 83% |
| Aroon ODDS (%) | 4 days ago 82% | 4 days ago 75% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| LMPLX | 53.27 | 0.62 | +1.18% |
| ClearBridge Large Cap Growth R | |||
| MXLGX | 10.58 | 0.05 | +0.47% |
| Empower Large Cap Growth Inv | |||
| PEQKX | 27.82 | 0.09 | +0.32% |
| Victory Pioneer Equity Income R6 | |||
| LCMIX | 45.07 | 0.03 | +0.07% |
| ClearBridge Mid Cap Growth IS | |||
| GCEPX | 12.44 | -0.05 | -0.40% |
| Goldman Sachs Clean Energy Income P | |||
INGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, INGN has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if INGN jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To INGN | 1D Price Change % | ||
|---|---|---|---|---|
| INGN | 100% | +0.47% | ||
| VCYT - INGN | 46% Loosely correlated | -22.52% | ||
| STRRP - INGN | 44% Loosely correlated | +0.20% | ||
| OSUR - INGN | 39% Loosely correlated | +2.02% | ||
| ENOV - INGN | 38% Loosely correlated | -0.51% | ||
| LIVN - INGN | 35% Loosely correlated | -1.12% | ||
More | ||||